Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.

MLA

Spitzer, Thomas R., et al. “Nonmyeloablative Haploidentical Stem-Cell Transplantation Using Anti-CD2 Monoclonal Antibody (MEDI-507)-Based Conditioning for Refractory Hematologic Malignancies.” Transplantation, vol. 75, no. 10, May 2003, pp. 1748–51. EBSCOhost, https://doi.org/10.1097/01.TP.0000064211.23536.AD.

APA

Spitzer, T. R., McAfee, S. L., Dey, B. R., Colby, C., Hope, J., Grossberg, H., Preffer, F., Shaffer, J., Alexander, S. I., Sachs, D. H., & Sykes, M. (2003). Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation, 75(10), 1748–1751. https://doi.org/10.1097/01.TP.0000064211.23536.AD

Chicago

Spitzer, Thomas R, Steven L McAfee, Bimalangshu R Dey, Christine Colby, James Hope, Howard Grossberg, Frederic Preffer, et al. 2003. “Nonmyeloablative Haploidentical Stem-Cell Transplantation Using Anti-CD2 Monoclonal Antibody (MEDI-507)-Based Conditioning for Refractory Hematologic Malignancies.” Transplantation 75 (10): 1748–51. doi:10.1097/01.TP.0000064211.23536.AD.